Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: Our results

Journal of Cardiovascular Medicine

Volumn 7, Issue 12, 2006, Pages 866-871

  Capuano, Cinzia ^a,b   Sesana, Marco ^a   Leonzi, Ornella ^a   Cuccia, Claudio ^a  

^a Fondazione Poliambulanza Istituto Ospedaliero   (Italy)

^b Fondazione Poliambulanza   (Italy)

Author keywords

Angioplasty; Coronary disease; Heparin; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CREATINE KINASE; CREATINE KINASE MB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; BOLUS INJECTION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CORONARY STENT; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FALSE ANEURYSM; FEMALE; FISTULA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HIGH RISK PATIENT; HUMAN; INCIDENCE; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; Q WAVE; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; WHOLE BLOOD COAGULATION TIME;

EID: 33751365498     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000253830.64753.0b     Document Type: Article

References (27)

1. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 23:1061-1065.
2. Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996; 93:667-671.
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330:956-961.
4. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349:1429-1435.
5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352:87-92.
6. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336:1689-1696.
7. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al., for the ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy Trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial. A randomized controlled trial. JAMA 2001; 285:2468-2473.
8. Danzi GB, Capuano C, Sesana M, Baglini R. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement. Catheter Cardiovasc Interv 2004; 61:179-184.
9. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113:156-175.
10. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11:1-11.
11. Glantz SA. Confidence intervals. In: Glantz SA, editor. Primer of biostatistics, 3rd ed. New York: McGraw-Hill, Health Professions Division; 1992. pp. 188-217.
12. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103:961-966.
13. Pinto DS, Lorenz DP, Murphy SA, Marble SJ, DiBattiste PM, Demopoulos LA, et al., for the TIMI StudyGroup. Association of an activated clotting time ≤250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). Am J Cardiol 2003; 91:976-978.
14. Brener SJ, Bhatt DL, Moliterno DJ, Schneider JP, Ellis SG, Topol EJ. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. Am J Cardiol 2003; 92:1468-1471.
15. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al., for the CREDO Investigators (Clopidogrel for the Reduction of Events During Observation). Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420.
16. Topol EJ, Moliterno DJ, Hermann HC, Powers ER, Grines CL, Cohen DJ, et al., for the TARGET Investigators (Do Tirofiban and ReoPro Give Similar Efficacy Trial). Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-1894.
17. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, et al., for the REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004; 93:1092-1096.
18. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al., for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853-863.
19. Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, et al. Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes - observations from the TARGET trial. Am J Cardiol 2003; 92:125-129.
20. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75:559-562.
21. Chew DP, Bhatt DL, Robbins MA, Mukherjee D, Roffi M, Schneider JP, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001; 88:672-674.
22. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804-847.
23. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341:319-327.
24. Koch KC, vom Dahl J, Kleinhans E, Klues HG, Radke PW, Ninnemann S, et al. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol 1999; 33:998-1004.
25. Denardo SJ, Davis KE, Reid PR, Tcheng JE. Efficacy and safety of minimal dose (≤1000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. Am J Cardiol 2003; 91:1-5.
26. Vainer J, Fleisch M, Gunnes P, Ramamurthy S, Garachemani A, Kaufmann UP, et al. Low-dose heparin for routine coronary angioplasty and stenting. Am J Cardiol 1996; 78:964-966.
27. Koch KT, Piek JJ, de Winter RJ, David GK, Mulder K, Tijssen JG, et al. Safety of low dose heparin in elective coronary angioplasty. Heart 1997; 77:517-522.